source
- AstraZeneca's breast cancer drug camizestrant fails pivotal first-line trialAstraZeneca announced that its investigational breast cancer drug camizestrant did not meet primary endpoints in a pivotal Phase 3 trial evaluating it as a first-line treatment for advanced disease…
- Eli Lilly halts early-stage obesity drug LY4064912 after failing to meet development criteriaEli Lilly announced it is ending development of its early-stage obesity candidate, LY4064912, after the phase 1 study did not achieve the company’s expectations. The first‑in‑human trial enrolled…